PDCD1 and neoplasm: When combined with anti‐PD‐1 and anti‐CTLA‐4, the nanodisc vaccine led to complete tumor regression in ≈88% of mice bearing MC‐38 tumors and ≈90% of mice bearing B16F10 tumors, compared to only ≈25% and ≈38% of mice having complete tumor regression after treatment with free CpG plus peptide neoantigen.97 The same group also reported delivering immunogenic chemotherapeutics98, 99, 100, 101 using the same type of nanodisc.